| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | 7 | GlobeNewswire (Europe) | SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced... ► Artikel lesen | |
| 18.04. | Oncternal Therapeutics: Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer | 52 | GlobeNewswire (Europe) | SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today... ► Artikel lesen | |
| 15.03. | Oncternal Therapeutics: Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer | 2 | GlobeNewswire (USA) | ||
| 08.03. | Oncternal Therapeutics files for mixed shelf offering | 3 | Seeking Alpha | ||
| 08.03. | Oncternal Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 07.03. | Recap: Oncternal Therapeutics Q4 Earnings | 1 | Benzinga.com | ||
| 07.03. | Oncternal Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 07.03. | Oncternal Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.03. | Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results | 44 | GlobeNewswire (Europe) | Third dosing cohort fully enrolled for our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant... ► Artikel lesen | |
| 06.03. | Oncternal Therapeutics Q4 2023 Earnings Preview | 1 | Seeking Alpha | ||
| 06.03. | Oncternal Therapeutics' Earnings: A Preview | 2 | Benzinga.com | ||
| 20.02. | ONCT-808 by Oncternal Therapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval | 3 | Pharmaceutical Technology | ||
| 06.02. | Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference | 2 | GlobeNewswire (USA) | ||
| 01.02. | Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 23.01. | Oncternal Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 08.01. | Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer | 342 | GlobeNewswire (Europe) | SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced... ► Artikel lesen | |
| 05.01. | Oncternal Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 04.01. | Oncternal Therapeutics Announces Reverse Stock Split | 277 | GlobeNewswire (Europe) | SAN DIEGO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced... ► Artikel lesen | |
| 02.01. | Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | 208 | GlobeNewswire (Europe) | SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced... ► Artikel lesen | |
| 28.12.23 | Oncternal Therapeutics reports patient death in CAR-T dose-escalation study | 2 | FierceBiotech |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 2.566 |
| NEL | 1.507 |
| APPLE | 1.412 |
| BYD | 1.321 |
| BAYER | 1.314 |
| SUPER MICRO COMPUTER | 1.232 |
| DEUTSCHE BANK | 1.130 |
| TUI | 1.097 |
| NVIDIA | 1.077 |
| PLUG POWER | 942 |
| TESLA | 900 |
| DAIMLER TRUCK | 886 |
| MERCEDES-BENZ | 825 |
| RWE | 796 |
| RHEINMETALL | 784 |
| AURUBIS | 745 |
| RENK GROUP | 709 |
| VOLKSWAGEN | 703 |
| DEUTSCHE LUFTHANSA | 694 |
| COMMERZBANK | 684 |
| AMAZON | 660 |
| SIEMENS ENERGY | 638 |
| AIXTRON SE | 606 |
| SIXT SE VZ | 594 |
| NOVO NORDISK | 552 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
